Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC by Jebbink, M., de Langen, A.J., Monkhorst, K., Boelens, M.C., van den Broek, D., van der Noort, V., de Gooijer, C.J., Mahn, M., van der Wekken, A.J., Hendriks, L., Hashemi, S.M.S., Paats, M.S., Dingemans, A.C., Smit, E.F.

Get full text

First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma? by Douma, L.H., Baas, P., de Gooijer, C.J.

Get full text

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma by Dumoulin, D W, Douma, L H, Hofman, M M, van der Noort, V, Cornelissen, R, de Gooijer, C J, Burgers, J A, Aerts, J G J V

Get full text

OA04.06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA) by Douma, L.-A.H., de Gooijer, C.J., Noort, V.v.d., Lalezari, F., de Vries, J.F., Vermeulen, M., Schilder, B., Smesseim, I., Baas, P., Burgers, J.A.

Get full text

MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial by Jebbink, M., Langen, A.J. De, Monkhorst, K., Boelens, M.c., Van Den Broek, D., Van Der Noort, V., Gooijer, C.J. De, Wekken, A.J. Van Der, Hendriks, L., Hashemi, S.M.S., Paats, M.S., Dingemans, A., Smit, E.

Get full text